Table 3.
Cox proportional hazards analyses, all patients (n= 379)*
| Stage/score | HR | 95% CI | P-value | c-statistic |
|---|---|---|---|---|
| Okuda staging system | ||||
| A (n= 73) | Ref. | – | 0.62 | 0.50 |
| B (n= 228) | 0.85 | 0.58–1.24 | ||
| C (n= 3) | 1.52 | 0.20–11.67 | ||
| IHPBA staging system | ||||
| T1 (n= 69) | Ref. | – | 0.62 | 0.52 |
| T2 (n= 284) | 1.11 | 0.72–1.70 | ||
| T3 (n= 26) | 1.42 | 0.71–2.83 | ||
| CLIP score | ||||
| 0 (n= 215) | Ref. | – | 0.48 | 0.51 |
| 1 (n= 83) | 1.32 | 0.89–1.94 | ||
| 2 (n= 20) | 1.56 | 0.70–3.46 | ||
| 3 (n= 2) | 1.45 | 0.19–10.9 | ||
| BCLC staging system | ||||
| 0 (n= 69) | Ref. | – | 0.74 | 0.51 |
| A1–A3 (n= 263) | 1.11 | 0.72–1.71 | ||
| A4 (n= 47) | 1.26 | 0.70–2.29 | ||
| JIS score | ||||
| 0 (n= 52) | Ref. | – | 0.35 | 0.52 |
| 1 (n= 259) | 1.23 | 0.76–2.00 | ||
| 2 (n= 56) | 1.53 | 0.83–2.81 | ||
| 3 (n= 12) | 2.32 | 0.85–6.36 | ||
| AJCC/UICC staging system | ||||
| T1 (n= 256) | Ref. | – | <0.001 | 0.59 |
| T2 (n= 123) | 2.17 | 1.61–2.93 | ||
| Early HCC prognostic score | ||||
| 0 (n= 59) | Ref. | – | <0.001 | 0.600 |
| 1 (n= 225) | 1.18 | 0.72–1.95 | ||
| 2 (n= 95) | 2.46 | 1.44–4.19 |
*
All models were stratified by type of surgery to account for differential survival between treatment modalities
HR, hazard ratio; CI, confidence interval; Ref., referent; IHPBA, International Hepato-Pancreato-Biliary Association; CLIP, Cancer of the Liver Italian Programme; BCLC, Barcelona Clinic Liver Cancer; JIS, Japanese Integrated Staging; AJCC/UICC, American Joint Committee on Cancer/International Union Against Cancer, 6th edition; HCC, hepatocellular carcinoma